Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06966700

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Inova Schar Cancer Institute ( Site 0025), Fairfax
Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian
VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond
a 1 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06312176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Charlottesville
Research Site, Fairfax
Research Site, Midlothian
a 2 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Virginia Cancer Specialists, Fairfax

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07007559

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Fort Belvoir
Clinical Trial Site, Midlothian
Clinical Trial Site, Norfolk

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Inova, Fairfax

Prebieha nábor

Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Virginia Cancer Specialists, Fairfax

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07174336

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

Adult Outpatient Pavilion, Richmond
Cellular Immunotherapies and Transplant Department, Richmond
VCU Health at Stony Point, Richmond

Prebieha nábor

Vek 18 a viac · Ženy · Aktualizované 22. 9. 2026 · NCT07426913

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

University of Virginia Health System, Charlottesville
Inova Schar Cancer Institute, Fairfax

Prebieha náborFáza 2

Vek 18 a viac · Ženy · Aktualizované 22. 9. 2026 · NCT07287098

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

Next Virginia, Fairfax

Prebieha náborFáza 1

Vek 18 a viac · Ženy · Aktualizované 21. 9. 2026 · NCT07524855

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Bon Secours Cancer Institute at Memorial Regional, Mechanicsville
Bon Secours St. Francis Medical Center, Midlothian
Bon Secours Cancer Institute at St. Mary's, Richmond

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NEXT Oncology, Fairfax

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07109726

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Inova Schar Cancer Institute, Fairfax
Virginia Cancer Specialists, Fairfax
Virginia Oncology Associates, Newport News
a 2 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT06492616

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Virginia Oncology Associates (VOA) ( Site 8001), Norfolk

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT06797635

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Virginia Cancer Specialists, Fairfax

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NEXT Oncology - Virginia Cancer Specialists, Fairfax

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06253871

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NEXT Oncology, Fairfax

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06440005

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Virginia Cancer Institute, Norfolk

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT05386108

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Midlothian

Prebieha náborFáza 3

Vek 18 až 130 · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT07647328

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Virginia Oncology Associates (Norfolk) - USOR, Norfolk

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT07100106

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Virginia Cancer Specialists-Fairfax, Fairfax

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07287917

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Next Oncology, Fairfax

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT05315700

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Virginia Cancer Specialists, PC, Fairfax
Virginia Oncology Associates, Norfolk

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT06982521

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

NEXT Virginia, Fairfax

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07287995

The Vanguard Study: Testing a New Way to Screen for Cancer

Sentara Martha Jefferson Hospital, Charlottesville
Inova Schar Cancer Institute, Fairfax
Inova Fair Oaks Hospital, Fairfax
a 5 ďalších

Prebieha náborVítaní zdravých dobrovoľníkov

Vek 45 až 75 · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT06995898

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Kaiser Permanente-Burke Medical Center, Burke
University of Virginia Cancer Center, Charlottesville
Augusta Health Center for Cancer and Blood Disorders, Fishersville
a 12 ďalších

Prebieha náborFáza 3

Vek 18 až 60 · Ženy · Aktualizované 2. 9. 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT06072612

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NEXT Virginia, Fairfax

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT07029399

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

NEXT Virginia, Fairfax

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 26. 8. 2026 · NCT07383506

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.